Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Recce PharmaceuticalsASX:RCE +4.17%20 EV-to-OCF is -5.33 as of Jul. 28, 2026. GuruFocus rates ASX:RCE with a GF Score™ of 20/100. The stock has 4 warning signs investors should review. Among 1,407 Biotechnology companies, Recce Pharmaceuticals ranks better than 57.29% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Recce Pharmaceuticals's Enterprise Value is A$122.64 Mil.
Recce Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-23.01 Mil. Therefore, Recce Pharmaceuticals's EV-to-OCF for today is -5.33.
The historical rank and industry rank for Recce Pharmaceuticals's EV-to-OCF or its related term are showing as below:
ASX:RCE'
s EV-to-OCF Range Over the Past 10 Years
Min: -5.14 Med: 0 Max: -5.14
Current: -5.14
During the past 10 years, the highest EV-to-OCF of Recce Pharmaceuticals was -5.14. The lowest was -5.14. And the median was .
ASX:RCE's EV-to-OCF is ranked better than 57.29% of 1407
companies
in the Biotechnology industry
Industry Median: -3.31
vs ASX:RCE: -5.14
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Recce Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Recce Pharmaceuticals's share price for today is A$0.375.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Recce Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.114.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Recce Pharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recce Pharmaceuticals EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Recce Pharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Recce Pharmaceuticals's EV-to-OCF falls into.
Recce Pharmaceuticals's current Enterprise Value is A$122.64 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Recce Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-23.01 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Recce Pharmaceuticals (ASX:RCE) has a EV-to-OCF of -5.33 as of Jul. 28, 2026. According to the industry distribution chart, Recce Pharmaceuticals ranks #601 out of 1407 companies in the Biotechnology industry, placing it in the top 42.7%.
Is Recce Pharmaceuticals' EV-to-OCF too high?
Recce Pharmaceuticals' current EV-to-OCF is -5.33. Based on the distribution chart, Recce Pharmaceuticals ranks #601 out of 1407 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Recce Pharmaceuticals has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Recce Pharmaceuticals' EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Recce Pharmaceuticals ranks #601 out of 1407 companies for EV-to-OCF. This puts Recce Pharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Recce Pharmaceuticals's current EV-to-OCF is -5.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recce Pharmaceuticals stock overvalued right now?
Recce Pharmaceuticals (ASX:RCE) has a current EV-to-OCF of -5.33. The current EV-to-OCF is -5.33. Recce Pharmaceuticals' overall GF Score™ is 20/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Recce Pharmaceuticals (ASX:RCE), the current EV-to-OCF is -5.33 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Recce Pharmaceuticals Ltd is an Australia-based, globally-focused biotechnology company that is pioneering the development and commercialisation of a drug discovery and development business commercialising new Classes of synthetic anti-infectives with broad-spectrum activity designed to address the urgent health threat of antibiotic-resistant superbugs and emerging viral pathogens. Its patented candidate, RECCE 327, has been developed for the treatment of life-threatening bacterial infections. It has one segment, which is the research and development of pharmaceutical drugs. Geographic segments are Australia, the UK, and the USA, of which the majority of the revenue comes from Australia. It offers antibiotic drugs to treat bacterial infections for Sepsis, Escherichia coli, and Others.
20GF Score
Get the complete analysis for ASX:RCE
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RCE has been successfully added to your 
